PROGRAM CHAIR
John L. Marshall, MD
Physician Executive Director, Medstar Washington DC Integrated Hematology Oncology Division
Director, The Ruesch Center for the Cure of GI Cancers
Frederick P. Smith Endowed Chair
Chief Medical Officer, Lombardi Comprehensive Cancer Center
Georgetown University Medical Center
Washington, DC
FACULTY PRESENTERS
Thomas H. Cartwright, MD
Associate Professor of Medicine
University of Central Florida School of Medicine
Ocala, FL
Richard F. Dunne, MD, MS-CI
Associate Professor of Medicine
Leader, Gastrointestinal Cancer Unit
Wilmot Cancer Institute, University of Rochester
Rochester, NY
Ronan J. Kelly MD, MBA
Director of Oncology, Charles A. Sammons Cancer Center
Baylor University Medical Center
Dallas, TX
PROGRAM DESCRIPTION
This enduring program will provide clinicians who care for people with gastric and gastroesophageal junction cancers with important updates about current and future management of the diseases. It includes two animations and case study discussions.
TARGET AUDIENCE
This activity is designed to meet the educational needs of community medical oncologists, internal medicine physicians, primary care physicians, pathologists and others (e.g., nurse practitioner, pharmacist, physician assistant, oncology nurse) involved in the management of patients with gastric and gastroesophageal junction cancers.
LEARNING OBJECTIVES
- Examine HER2 levels of expression and their application to patients with advanced gastric and gastroesophageal junction cancers
- Apply both clinical trial findings and guideline recommendations to the treatment of patients with advanced HER2 gastric and gastroesophageal junction cancers
- Discuss the recognition and management of HER2-targeted ADC treatment emergent adverse events in patients with gastrointestinal cancers
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
JOINT ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Med Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NURSES (ANCC) CREDIT DESIGNATION
Amedco LLC designates this activity for a maximum of 1.0 ANCC contact hours.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIP(S)
| Faculty Member | Disclosures |
| John L. Marshall, MD | Discloses that he has served on a speakers bureau, and received fees for non-CME/CE services from Astra Zeneca, Merck, Bayer, Taiho, Seagen, Pfizer, Takeda, Arcus and Caris. |
| Thomas H. Cartwright, MD | Has no relevant financial relationships to disclose. |
| Richard F. Dunne, MD, MS-CI | Discloses that he has received consulting fees from Toray Industries Inc; and has served on an advisory board for Exelixis Inc. and Merck & Co. |
| Ronan J. Kelly MD, MBA | Discloses that he has received consulting fees from Astra Zeneca, Daicchi Sankyo, Bristol Myers Squibb, Merck, Eli Lilly, Astellas, Toray, Allarity, Steris, Novocure, Illumina, Grail, Exact Sciences, OncoHost, Amgen, and Eisai; has served on a speakers bureau for Bristol Myers Squibb; and has received research funds from Bristol Myers Squibb and Eli Lilly. |
All relevant financial relationships have been mitigated.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
Staff, Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME/CE activity:
- Matthew Frese, General Manager of Med Learning Group has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group has nothing to disclose.
- Lauren Welch, MA, VP, Outcomes and Accreditation for Med Learning Group has nothing to disclose.
- Anita Mirsa-Press, Medical Director for Med Learning Group, has nothing to disclose.
- Melissa A Johnson, Sr. Program Manager for Med Learning Group has nothing to disclose.
- Millena DeBrito, Program Coordinator for Med Learning Group has nothing to disclose.
- Russie Allen, Accreditation and Outcomes Manager for Med Learning Group has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity.
In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation.
Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at [email protected]
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group at [email protected]
RELEASED DATE: January 05, 2024
EXPIRATION DATE: January 05, 2025
Copyright © 2023 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
